{"gene":"LZTR1","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2005,"finding":"LZTR1 (LZTR-1) localizes exclusively to the cytoplasmic surface of the Golgi network, with this localization mediated by its second BTB/POZ domain. Treatment with brefeldin A causes LZTR1 to redistribute into dispersed punctuated structures that co-localize with the Golgi marker GM130, identifying it as a Golgi matrix-associated protein. Upon induction of apoptosis, LZTR1 is phosphorylated on tyrosine residues and subsequently degraded via caspase- and proteasome-dependent pathways.","method":"Confocal microscopy with Golgi markers (GM130, Golgin-97, TGN46), brefeldin A treatment, co-localization with actin, caspase inhibitor (Z-VAD-fmk) and proteasome inhibitor (lactacystin, MG132) rescue experiments, domain-deletion analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiments with functional consequence (apoptosis-linked degradation), multiple orthogonal methods, single lab","pmids":["16356934"],"is_preprint":false},{"year":2018,"finding":"LZTR1 functions as a CUL3 (cullin 3) ubiquitin ligase adaptor that ubiquitinates RAS GTPases (KRAS, HRAS, NRAS, MRAS) at lysine-170 (HRAS) and lysine-127 (MRAS). LZTR1-mediated ubiquitination at K170 inhibits RAS signaling by attenuating RAS association with the plasma membrane. Disease-associated LZTR1 mutations disrupt either LZTR1-CUL3 complex formation or LZTR1 interaction with RAS proteins.","method":"LZTR1 complex trapping from intact mammalian cells, ubiquitome mass spectrometry analysis, site-directed mutagenesis (K170 on HRAS, K127 on MRAS), membrane localization assays, mouse haploinsufficiency model recapitulating Noonan syndrome phenotypes, Schwann cell knockout driving dedifferentiation and proliferation","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — reconstitution-level trapping, ubiquitome MS with site-specific mutagenesis, in vivo mouse model, replicated independently in same issue by Bigenzahn et al.","pmids":["30442762"],"is_preprint":false},{"year":2018,"finding":"Inactivation of LZTR1 (the CUL3 adaptor) in human CML cells leads to enhanced MAPK pathway activity and reduced sensitivity to tyrosine kinase inhibitors. Endogenous human LZTR1 associates with the main RAS isoforms. LZTR1 inactivation causes decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS. Knockdown of the Drosophila LZTR1 ortholog CG3711 results in a Ras-dependent gain-of-function phenotype.","method":"Genetic screens in CML cells, siRNA knockdown in human cells, co-immunoprecipitation of endogenous LZTR1 with RAS isoforms, membrane localization assays, Drosophila CG3711 knockdown with genetic epistasis","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP of endogenous proteins, genetic epistasis in Drosophila, functional phenotype in human cells, independently corroborated by Steklov et al. in same issue","pmids":["30442766"],"is_preprint":false},{"year":2019,"finding":"LZTR1 promotes polyubiquitination and proteasomal degradation of RAS GTPases (HRAS, NRAS, KRAS, MRAS), including oncogenic RAS mutants, via ubiquitin chains containing K48, K63, and K33 linkages. MRAS-K127 and HRAS-K170 are ubiquitination sites. LZTR1-mediated RAS degradation inhibits ERK1/2 activation and cell growth. LZTR1 also interacts with autophagy proteins LC3B and SQSTM1/p62, and co-expression of LZTR1 and RAS increases lipidated LC3B, but long-term chloroquine treatment has minimal effect on RAS levels, indicating autophagy plays a minor role compared to proteasomal degradation.","method":"In vivo ubiquitination assays, immunoprecipitation, western blotting, site-directed mutagenesis of ubiquitination sites, chloroquine treatment, LC3B lipidation assay, ERK1/2 activation assays, cell proliferation assays","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vivo ubiquitination assays with site-specific mutagenesis, multiple RAS isoforms tested, multiple orthogonal methods, independently corroborates Steklov et al. findings","pmids":["31337872"],"is_preprint":false},{"year":2019,"finding":"LZTR1 acts as an adaptor for proteasomal degradation of the RAS GTPase RIT1. Pathogenic mutations in either RIT1 (near switch II domain) or LZTR1 result in incomplete degradation of RIT1, causing RIT1 accumulation and dysregulated growth factor signaling. LZTR1 was identified as a RIT1 interactor by mass spectrometry.","method":"Mass spectrometry identification of RIT1-LZTR1 interaction, isogenic germline knock-in mouse model (RIT1 mutation), functional degradation assays, growth factor signaling readouts","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — MS identification confirmed with functional in vivo mouse model, mechanistic degradation assays, multiple orthogonal approaches","pmids":["30872527"],"is_preprint":false},{"year":2019,"finding":"Dominant Noonan syndrome-causing LZTR1 mutations do not disrupt binding to CUL3 but are predicted to affect the Kelch domain surface mediating substrate binding. These dominant mutations enhance stimulus-dependent RAS-MAPK signaling, at least partly by increasing the RAS protein pool. Dominant NS mutations do not affect LZTR1 protein stability or subcellular localization, unlike missense changes occurring in recessive NS.","method":"Transfection of NS-associated LZTR1 mutants, MAPK pathway activation assays (phospho-ERK), RAS protein level measurements, co-immunoprecipitation with CUL3, subcellular localization analysis, protein stability assays, structural modeling of Kelch domain","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays in cell lines, Co-IP with CUL3, single lab, no in vivo validation","pmids":["30481304"],"is_preprint":false},{"year":2018,"finding":"LZTR1 binds to the RAF1-PPP1CB complex as detected by immunoprecipitation of endogenous LZTR1. Cells transfected with siRNA against LZTR1 show decreased levels of RAF1 phosphorylated at Ser259, indicating LZTR1 modulates RAF1 phosphorylation status within the RAS/MAPK pathway.","method":"Endogenous co-immunoprecipitation followed by western blotting, siRNA knockdown of LZTR1, phospho-RAF1 (Ser259) western blotting","journal":"Human genetics","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — reciprocal endogenous Co-IP and functional knockdown result, single lab, two orthogonal methods","pmids":["30368668"],"is_preprint":false},{"year":2020,"finding":"LZTR1 (night owl/nowl) negatively regulates Ras signaling and interacts genetically with Neurofibromin-1 (Nf1) in the control of night-time sleep in Drosophila. Knockdown of nowl or Nf1 in GABA-responsive sleep-promoting neurons elicits a sleep phenotype that can be rescued by increased GABAA receptor signaling, indicating Nowl regulates sleep through modulation of GABA signaling. Nowl is also required for metabolic homeostasis.","method":"Drosophila genetic loss-of-function (nowl knockdown), genetic epistasis with Nf1 mutants, tissue-specific knockdown in GABAergic neurons, GABAA receptor pharmacological rescue, sleep behavior quantification, metabolic assays","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with defined cellular phenotype in Drosophila model, multiple orthogonal methods, single lab","pmids":["32339168"],"is_preprint":false},{"year":2020,"finding":"LZTR1 controls cardiovascular function by regulating vesicular trafficking. LZTR1 affects dynamics of fusion and fission of recycling endosomes by controlling ubiquitination of the ESCRT-III component CHMP1B (charged multivesicular protein 1B). NS-associated LZTR1 mutations diminish CHMP1B ubiquitination. LZTR1-mediated dysregulation of CHMP1B ubiquitination triggers endosomal accumulation and subsequent activation of VEGFR2, and decreases blood levels of soluble VEGFR2. Whole-body and vascular-specific Lztr1 knockout causes perinatal lethality from cardiovascular dysfunction; Lztr1 deletion in adult blood vessels leads to abnormal vascular leakage with defective adherent and tight junctions due to dysregulated vesicular trafficking.","method":"Conditional and whole-body Lztr1 knockout mice, endothelial-specific knockout, vascular permeability assays, endosomal trafficking assays, ubiquitination assays for CHMP1B, VEGFR2 activity measurements, ELISA for soluble VEGFR2, cediranib (VEGFR2 inhibitor) rescue experiments","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vivo knockout models with defined vascular phenotype, ubiquitination assays identifying novel substrate CHMP1B, rescue with VEGFR2 inhibitor, multiple orthogonal methods","pmids":["32175818"],"is_preprint":false},{"year":2022,"finding":"In both fruit flies and mice, LZTR1 shows a biochemical preference for RIT1 orthologs over classical RAS GTPases. Embryonic lethality of homozygous Lztr1 null mice can be rescued by deletion of Rit1, demonstrating genetic epistasis and establishing RIT1 orthologs as the preferred in vivo substrates of LZTR1.","method":"Lztr1 loss-of-function mutants in Drosophila and mice, Rit1 knockout rescue of Lztr1 null lethality, biochemical substrate preference assays, genetic epistasis analysis","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — cross-species genetic epistasis with defined rescue of lethal phenotype, biochemical substrate preference, multiple organisms","pmids":["35467524"],"is_preprint":false},{"year":2022,"finding":"LZTR1 deficiency increases accumulation of RAS subfamily members and enhances cell proliferation, invasion, and xenograft tumor growth. LZTR1 inhibits KLHL12-mediated ubiquitination of SEC31A (a COPII component), and LZTR1 deficiency promotes collagen secretion via KLHL12. LZTR1-RIT1 and LZTR1-KLHL12 interactions are independent and do not directly interfere with each other. LZTR1 functions as a repressor of BTB-Kelch family member KLHL12.","method":"LZTR1 knockout in lung adenocarcinoma cells, multi-omics analysis, co-immunoprecipitation identifying KLHL12 interaction, SEC31A ubiquitination assays, collagen secretion assays, xenograft tumor growth assays, EMT marker analysis under TGF-β1 treatment","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP identifying novel substrate KLHL12 with functional ubiquitination assays and collagen secretion readout, single lab, multiple orthogonal methods","pmids":["37626065"],"is_preprint":false},{"year":2022,"finding":"GSK3 regulates LZTR1 function: inhibiting or silencing GSK3 in pancreatic cancer cells leads to a decline in Ras protein levels (wild-type and oncogenic KRAS) via a 3-fold decrease in Ras protein half-life. This decline is blocked by proteasome inhibition or LZTR1 knockdown, establishing a GSK3-regulated LZTR1-dependent mechanism controlling Ras protein stability and cell proliferation.","method":"GSK3 inhibitor treatment and siRNA knockdown in pancreatic cancer cells, LZTR1 siRNA knockdown, protein half-life measurements, proteasome inhibition rescue, cell proliferation assays","journal":"Neoplasia (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis via double knockdown (GSK3 + LZTR1), half-life measurements, proteasome rescue, single lab","pmids":["35114566"],"is_preprint":false},{"year":2023,"finding":"LZTR1 is the substrate-specific adaptor of a CUL3-dependent ubiquitin ligase that targets EGFR and AXL receptor tyrosine kinases for ubiquitin-dependent degradation in the lysosome. Pathogenic cancer-associated LZTR1 mutations fail to promote EGFR and AXL degradation, resulting in dysregulated growth factor signaling. Conditional inactivation of Lztr1 and Cdkn2a in the mouse nervous system causes schwannoma-like tumors with aberrant accumulation of EGFR and AXL.","method":"Unbiased biochemical screens (Co-IP/MS) identifying EGFR and AXL as LZTR1 interactors, ubiquitination and degradation assays, lysosomal pathway determination, Lztr1/Cdkn2a conditional mouse knockout, EGFR+AXL co-inhibition in tumor models","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — unbiased screen followed by biochemical validation, in vivo mouse model, mechanistic degradation assays identifying lysosomal pathway, multiple orthogonal methods","pmids":["36445254"],"is_preprint":false},{"year":2024,"finding":"Oncogenic KRAS mutations G12D, G13D, and Q61H abrogate KRAS association with LZTR1, thereby affecting KRAS turnover by the CUL3/LZTR1 E3 ligase complex. Wild-type KRAS but not oncogenic mutants are efficiently captured by LZTR1.","method":"APEX2 proximity labeling of WT, G12D, G13D, and Q61H KRAS mutants, quantitative proteomics under starvation and stimulation conditions, differential LZTR1 capture analysis","journal":"Life science alliance","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proximity labeling proteomics with multiple KRAS mutants compared, single lab, no direct ubiquitination assay in abstract","pmids":["38453365"],"is_preprint":false},{"year":2024,"finding":"A homozygous LZTR1 L580P variant is predicted to alter binding affinity of dimerization domains, facilitating formation of linear LZTR1 polymers. This complex dysfunction results in accumulation of RAS GTPases and global pathological proteomic changes leading to cardiomyocyte hypertrophy. Cardiomyocyte-specific MRAS degradation is mediated by LZTR1 via non-proteasomal pathways, whereas RIT1 degradation is mediated by both LZTR1-dependent and LZTR1-independent pathways. Biallelic genetic correction of LZTR1 L580P rescues the molecular and cellular disease phenotype.","method":"Patient-specific and CRISPR-Cas9-corrected iPSC-derived cardiomyocytes, in silico polymer formation prediction, proteomics, RAS accumulation assays, CRISPR rescue experiments, pathway inhibitor studies","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — iPSC patient model with CRISPR correction (rescue), proteomics, functional hypertrophy readout, single lab","pmids":["39003740"],"is_preprint":false},{"year":2024,"finding":"LZTR1 autosomal dominant mutations (G245R and R409C, corresponding to human G248R and R412C) cause dominant-negative inhibition of wild-type LZTR1 function. These mutants do not interact with RIT1 and result in accumulation of MRAS and RIT1 in cardiomyocytes, activating the MAPK signaling pathway. MEK inhibitor trametinib treatment ameliorates cardiac hypertrophy in mutant mice.","method":"LZTR1 knock-in mice (Lztr1G245R/+ and Lztr1R409C/+), co-immunoprecipitation with RIT1, MRAS and RIT1 protein level assays in left ventricles, multi-omics analysis, trametinib treatment rescue","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knock-in mouse model with dominant-negative mechanism established by Co-IP and protein level assays, pharmacological rescue, single lab","pmids":["39352760"],"is_preprint":false},{"year":2024,"finding":"Novel small-molecule fragments (C53 and Z86) enhance the KRAS-LZTR1 protein-protein interaction in a dose-dependent manner, as shown by split-luciferase reporter assay, proximity biotinylation (BioID), thermal shift assays, and NMR spectroscopy. These fragments increase endogenous LZTR1 recruitment to KRAS.","method":"Split-luciferase-based reporter assay for KRAS-LZTR1 interaction, fragment library screen, BioID proximity biotinylation, thermal shift assays, NMR spectroscopy","journal":"ACS chemical biology","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal biophysical and cell-based methods validating PPI enhancement, single lab, no in vivo validation","pmids":["39194017"],"is_preprint":false},{"year":2025,"finding":"PP1C phosphatase dephosphorylates the conserved T148 residue on RAS, which permits LZTR1-dependent proteasomal degradation. Phosphorylation of RAS T148 by PAK1/2 kinases shields RAS from LZTR1-dependent degradation. KRAS A146 gain-of-function mutations (adjacent to T148) render LZTR1 ineffective at promoting degradation. KRAS protein is four-fold less stable in hematologic versus carcinoma cells due to this regulatory circuit.","method":"Multi-omics screening in multiple myeloma cells, phosphatase identification (PP1C), kinase identification (PAK1/2), T148 mutagenesis, LZTR1-dependent degradation assays, PAK1/2 inhibitor treatment, protein stability measurements","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — mechanistic dissection with site-specific mutagenesis and writer/eraser identification, multi-omics screen, preprint not yet peer-reviewed","pmids":["41542462"],"is_preprint":true},{"year":2025,"finding":"LZTR1 regulates MHC-I expression in epithelial cells through an NF-κB1-dependent mechanism. Mechanistically, LZTR1 modulates MHC-I transcription by regulating co-translational biogenesis of NF-κB1 (p50) in a ubiquitination-independent but proteasome-dependent manner through direct binding with ribosome and proteasome. Loss of LZTR1 leads to suppression of CD8+ TRM activation and proliferation and decreased IL-17A production.","method":"LZTR1 knockout in cutaneous and colonic epithelial cells/organoids, NF-κB1 (p50) processing assays, ribosome and proteasome co-immunoprecipitation, MHC-I expression assays, in vivo CD8+ TRM functional readouts","journal":"Cell discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding assays with ribosome/proteasome, functional in vivo readout, ubiquitination-independent mechanism established, single lab","pmids":["41162356"],"is_preprint":false},{"year":2025,"finding":"LZTR1 interacts with NOC2L (a histone acetyltransferase inhibitor), and this interaction is disrupted by dominant Noonan syndrome LZTR1 variants. Loss of LZTR1-NOC2L interaction leads to NOC2L upregulation, impaired p53 acetylation, reduced apoptosis, and compensatory increase in autophagy. LZTR1 variants are thermodynamically stable in vitro and associated with elevated pan-RAS levels and preferential activation of the DNA damage response.","method":"Mutagenesis of LZTR1 variants, phosphoproteomics, immunoblotting, immunofluorescence, nanoluciferase assays (PPI), in silico structural modeling, p53 acetylation assays, LC3 and phospho-p70 S6K measurements","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — nanoluciferase PPI assay plus phosphoproteomics and functional downstream readouts, single lab, interaction not yet independently replicated","pmids":["41175093"],"is_preprint":false},{"year":2025,"finding":"LZTR1 overexpression in melanoma activates ERBB3 receptor and its downstream targets PYK2 and SRC tyrosine kinases, enhancing cell invasion and actin cytoskeleton organization. LZTR1 associates with actin-related proteins. LZTR1 downregulation suppresses the protective autophagy-initiating factors ULK1 and AMBRA1, and upregulates SQSTM1/p62. LZTR1 regulates the ubiquitin proteasome system in melanoma cells.","method":"Proximity biotinylation and co-immunoprecipitation combined with LC-MS/MS proteomics, LZTR1 knockdown/overexpression in melanoma cells, invasion assays, ERBB3/PYK2/SRC pathway activation assays, autophagy marker measurements","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — BioID + Co-IP proteomics with functional pathway validation, single lab, multiple orthogonal methods","pmids":["40885854"],"is_preprint":false},{"year":2025,"finding":"In a cardiac-specific Lztr1 knockdown mouse model, Lztr1 deficiency activates the RAP1/MAPK/AKT signaling pathway leading to Ca2+ homeostasis disorder and cardiomyocyte apoptosis, recapitulating dilated cardiomyopathy pathology. The transcriptomic analysis identified the RAP1 pathway as a key downstream effector.","method":"CRISPR-Cas9/AAV9-mediated cardiac-specific Lztr1 knockdown (CASAAV system), cardiac function assays, transcriptomic sequencing, pathway analysis, mitochondrial and Ca2+ handling assays, apoptosis assays","journal":"International journal of biological macromolecules","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo cardiac-specific KO with transcriptomic pathway identification and functional readouts, single lab","pmids":["40967536"],"is_preprint":false},{"year":2025,"finding":"Full-length CRL3LZTR1-MRAS complex was successfully expressed and purified. MRAS binds tightly to LZTR1, in contrast to RIT1 and HRAS under these in vitro conditions. The presence of CRL3 (Cullin3 RING ligase) stabilizes and homogenizes LZTR1 by facilitating complex formation.","method":"BacMam expression system, protein purification and biochemical characterization, in vitro binding assays comparing MRAS, RIT1, and HRAS binding to LZTR1","journal":"Protein expression and purification","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct in vitro reconstitution and binding assay, but single lab and limited functional follow-up in abstract","pmids":["40204202"],"is_preprint":false},{"year":2021,"finding":"Conditional knockout of Lztr1 restricted to the telencephalon results in increased MAPK pathway activation in white matter regions, altered expression of stage-specific oligodendrocyte lineage markers with increased oligodendrocyte progenitor cells (OPCs) and decreased oligodendrocyte differentiation markers, and increased GFAP astrocyte marker expression.","method":"Foxg1-Cre conditional Lztr1 knockout mice, immunohistochemistry for oligodendrocyte lineage markers, GFAP staining, MAPK pathway activation assays (phospho-ERK), quantitative analysis of OPC and mature oligodendrocyte markers","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined cellular phenotype (oligodendrocyte differentiation block), MAPK activation measured, single lab","pmids":["34222248"],"is_preprint":false}],"current_model":"LZTR1 is a BTB-Kelch domain adaptor protein that associates with CUL3 (cullin 3) to form a RING E3 ubiquitin ligase complex, which ubiquitinates RAS GTPases (KRAS, HRAS, NRAS, MRAS, and especially RIT1) at conserved lysine residues (e.g., K170 on HRAS), promoting their proteasomal degradation and attenuating their membrane association and MAPK signaling; LZTR1 also ubiquitinates EGFR, AXL, and CHMP1B (for endosomal trafficking control), and regulates RAS stability through a GSK3-dependent and PAK1/2-T148 phosphorylation-governed circuit, while disease-associated mutations disrupt substrate binding, CUL3 interaction, or LZTR1 dimerization, collectively causing accumulation of RAS GTPases and hyperactivation of MAPK signaling that underlies schwannomatosis, Noonan syndrome, and various cancers."},"narrative":{"mechanistic_narrative":"LZTR1 is a BTB-Kelch substrate-specific adaptor for a CUL3 RING E3 ubiquitin ligase that restrains RAS-MAPK signaling by targeting RAS-family GTPases for ubiquitin-dependent degradation [PMID:30442762, PMID:30442766]. As the adaptor of the CRL3-LZTR1 complex, it ubiquitinates KRAS, HRAS, NRAS, and MRAS at conserved lysines (HRAS K170, MRAS K127), promoting their proteasomal turnover, attenuating their plasma-membrane association, and thereby dampening ERK1/2 activation and proliferation [PMID:30442762, PMID:31337872]; in vivo across flies and mice, RIT1 emerges as the genetically preferred substrate, since deletion of Rit1 rescues the lethality of Lztr1 loss [PMID:30872527, PMID:35467524]. Substrate engagement is gated by the GTPase nucleotide/mutational state and by post-translational marks: oncogenic KRAS mutations (G12D, G13D, Q61H, A146) abrogate LZTR1 capture and turnover [PMID:38453365, PMID:41542462], while a PAK1/2-phosphorylated/PP1C-dephosphorylated T148 switch and a GSK3-dependent input control RAS stability through LZTR1 [PMID:35114566, PMID:41542462]. Beyond RAS, LZTR1 directs CUL3-dependent lysosomal degradation of the receptor tyrosine kinases EGFR and AXL [PMID:36445254] and controls vesicular trafficking by ubiquitinating the ESCRT-III component CHMP1B to regulate recycling-endosome dynamics and VEGFR2 signaling [PMID:32175818]. Disease-associated mutations act through distinct mechanisms—disrupting substrate binding at the Kelch surface, CUL3 interaction, or LZTR1 dimerization—and dominant-negative variants poison wild-type LZTR1, causing accumulation of RAS/RIT1/MRAS and MAPK hyperactivation that underlies Noonan syndrome, schwannomatosis-like tumors, and cardiomyopathy, with MEK inhibition (trametinib) reversing cardiac phenotypes in mutant mice [PMID:30481304, PMID:36445254, PMID:39003740, PMID:39352760]. LZTR1 localizes to the cytoplasmic face of the Golgi via its second BTB domain [PMID:16356934].","teleology":[{"year":2005,"claim":"Established the first cellular context for LZTR1, defining where it resides before any enzymatic role was known.","evidence":"Confocal microscopy with Golgi markers, brefeldin A, and domain-deletion analysis in mammalian cells","pmids":["16356934"],"confidence":"Medium","gaps":["No molecular activity assigned at this stage","Functional consequence of Golgi localization for later-defined substrates unresolved","Tyrosine-phosphorylation/caspase degradation pathway not connected to ubiquitin ligase function"]},{"year":2018,"claim":"Resolved the core biochemical function: LZTR1 is a CUL3 adaptor that ubiquitinates RAS GTPases at defined lysines to limit membrane association and MAPK output.","evidence":"Complex trapping, ubiquitome MS, site-directed mutagenesis (HRAS K170, MRAS K127), membrane-localization assays, and mouse haploinsufficiency model; corroborated by genetic screens and endogenous reciprocal Co-IP plus Drosophila epistasis","pmids":["30442762","30442766"],"confidence":"High","gaps":["Ubiquitin chain linkage composition not yet defined","Relative ranking of RAS isoform substrates in vivo unresolved","Endosomal/RTK substrates not yet known"]},{"year":2018,"claim":"Connected LZTR1 to RAF1 phosphorylation, indicating it modulates signaling at additional nodes of the RAS/MAPK cascade.","evidence":"Endogenous Co-IP of LZTR1 with RAF1-PPP1CB and siRNA knockdown with phospho-RAF1 (Ser259) immunoblot","pmids":["30368668"],"confidence":"Medium","gaps":["Direct vs indirect effect on RAF1 phosphorylation not distinguished","No ubiquitination of RAF1 demonstrated","Single lab, two methods"]},{"year":2019,"claim":"Defined the degradation route and chain chemistry and identified RIT1 as a substrate, broadening the GTPase repertoire LZTR1 controls.","evidence":"In vivo ubiquitination assays with K48/K63/K33 linkage and site mutagenesis; MS identification of RIT1 interaction with isogenic knock-in mouse model","pmids":["31337872","30872527"],"confidence":"High","gaps":["Autophagy contribution minor but not fully delineated","Why RIT1 vs classical RAS preference unresolved at this stage"]},{"year":2019,"claim":"Distinguished dominant from recessive disease mechanisms, showing dominant Noonan mutations spare CUL3 binding and stability but impair substrate recognition.","evidence":"Transfection of NS-associated mutants with phospho-ERK, RAS level, CUL3 Co-IP, stability/localization assays, and Kelch-domain modeling","pmids":["30481304"],"confidence":"Medium","gaps":["No in vivo validation","Structural modeling not experimentally confirmed","Mechanism of dominant effect not fully resolved here"]},{"year":2020,"claim":"Extended LZTR1 substrate scope beyond RAS to CHMP1B, linking it to endosomal trafficking and cardiovascular VEGFR2 control.","evidence":"Conditional/whole-body and endothelial Lztr1 knockout mice, CHMP1B ubiquitination assays, VEGFR2 readouts, and cediranib rescue","pmids":["32175818"],"confidence":"High","gaps":["Relationship between RAS and CHMP1B substrate pathways unresolved","Structural basis of CHMP1B recognition unknown"]},{"year":2020,"claim":"Demonstrated conserved organismal physiology for LZTR1 RAS regulation, linking it to NF1 and GABAergic sleep control.","evidence":"Drosophila nowl loss-of-function, genetic epistasis with Nf1, tissue-specific knockdown, and GABAA pharmacological rescue","pmids":["32339168"],"confidence":"Medium","gaps":["Mammalian relevance of sleep phenotype untested","Direct substrate driving phenotype not identified"]},{"year":2021,"claim":"Showed LZTR1 loss perturbs CNS cell-fate decisions through MAPK hyperactivation, relevant to its tumor and developmental phenotypes.","evidence":"Foxg1-Cre conditional Lztr1 knockout mice with oligodendrocyte lineage marker analysis and phospho-ERK measurement","pmids":["34222248"],"confidence":"Medium","gaps":["Substrate driving lineage block not identified","Single lab descriptive phenotype"]},{"year":2022,"claim":"Established RIT1 orthologs as the genetically preferred in vivo substrate by rescuing lethality, ranking substrates physiologically.","evidence":"Lztr1 loss-of-function in fly and mouse with Rit1 knockout rescue and biochemical substrate-preference assays","pmids":["35467524"],"confidence":"High","gaps":["Biochemical basis of RIT1 preference vs classical RAS unresolved","Tissue-specific substrate hierarchy not mapped"]},{"year":2022,"claim":"Identified additional non-RAS roles—repression of KLHL12/SEC31A-mediated collagen secretion and a GSK3-dependent input controlling RAS stability.","evidence":"LZTR1 knockout in lung adenocarcinoma cells with KLHL12 Co-IP and SEC31A ubiquitination assays; GSK3 inhibition/knockdown with LZTR1-dependent half-life and proteasome-rescue assays in pancreatic cancer cells","pmids":["37626065","35114566"],"confidence":"Medium","gaps":["Mechanism by which GSK3 acts on the LZTR1-RAS axis undefined","KLHL12 repression mechanism single lab"]},{"year":2022,"claim":"Expanded substrate scope to receptor tyrosine kinases, showing LZTR1 routes EGFR and AXL to lysosomal degradation and that cancer mutations fail to do so.","evidence":"Unbiased Co-IP/MS, ubiquitination/degradation and lysosomal-pathway assays, and Lztr1/Cdkn2a conditional schwannoma mouse model with EGFR+AXL co-inhibition","pmids":["36445254"],"confidence":"High","gaps":["Why these substrates go to lysosome vs proteasome unresolved","CUL3-dependence of RTK degradation step not fully dissected"]},{"year":2024,"claim":"Showed substrate capture is gated by KRAS mutational state, explaining how oncogenic mutants evade LZTR1-mediated turnover.","evidence":"APEX2 proximity labeling and quantitative proteomics comparing WT and G12D/G13D/Q61H KRAS under starvation/stimulation","pmids":["38453365"],"confidence":"Medium","gaps":["No direct ubiquitination assay for the mutants in this study","Structural basis of impaired capture not shown"]},{"year":2024,"claim":"Defined two distinct disease-mutation mechanisms—dimerization-disrupting polymer formation and dominant-negative inhibition—both causing RAS/RIT1/MRAS accumulation and reversible by MEK inhibition.","evidence":"Patient/CRISPR-corrected iPSC cardiomyocytes with proteomics and rescue (L580P); Lztr1 G245R/R409C knock-in mice with RIT1 Co-IP, protein-level assays, and trametinib rescue","pmids":["39003740","39352760"],"confidence":"Medium","gaps":["Polymer-formation model partly in silico","Non-proteasomal MRAS degradation route in cardiomyocytes undefined","Single lab per model"]},{"year":2024,"claim":"Provided a structural/biochemical foothold by reconstituting the CRL3-LZTR1-MRAS complex and demonstrating CUL3-driven stabilization of LZTR1.","evidence":"BacMam expression, purification, and in vitro binding assays comparing MRAS, RIT1, and HRAS","pmids":["40204202"],"confidence":"Medium","gaps":["No high-resolution structure reported in abstract","Discrepancy with in vivo RIT1 preference unresolved","Limited functional follow-up"]},{"year":2024,"claim":"Identified small-molecule fragments that enhance the KRAS-LZTR1 interaction, establishing the complex as a druggable degradation-promoting target.","evidence":"Split-luciferase reporter, BioID, thermal shift, and NMR characterization of fragments C53/Z86","pmids":["39194017"],"confidence":"Medium","gaps":["No in vivo validation","Effect on KRAS degradation not directly demonstrated"]},{"year":2025,"claim":"Uncovered a phosphorylation switch (PAK1/2-PP1C at RAS T148) and tissue context that set whether LZTR1 can degrade RAS, explaining differential RAS stability across cancers.","evidence":"Multi-omics in multiple myeloma cells, writer/eraser identification (PAK1/2, PP1C), T148 mutagenesis, LZTR1-dependent degradation and stability assays (preprint)","pmids":["41542462"],"confidence":"Medium","gaps":["Preprint, not yet peer-reviewed","Structural basis of how T148 phosphorylation blocks LZTR1 capture unknown"]},{"year":2025,"claim":"Revealed ubiquitination-independent functions—co-translational regulation of NF-kB1/MHC-I via ribosome/proteasome binding and disruption of LZTR1-NOC2L controlling p53 acetylation—broadening LZTR1 mechanism beyond RAS degradation.","evidence":"LZTR1 knockout epithelial organoids with NF-kB1 processing and ribosome/proteasome Co-IP and CD8+ TRM readouts; nanoluciferase PPI, phosphoproteomics, and p53-acetylation assays for NOC2L","pmids":["41162356","41175093"],"confidence":"Medium","gaps":["Mechanism of co-translational p50 regulation incompletely defined","LZTR1-NOC2L interaction not independently replicated","Connection to canonical CUL3 adaptor role unresolved"]},{"year":2025,"claim":"Documented context-dependent pro-tumorigenic and cardiac roles—ERBB3/PYK2/SRC and actin-cytoskeleton effects in melanoma and RAP1/MAPK/AKT-driven cardiomyopathy—indicating LZTR1 output varies by tissue.","evidence":"BioID/Co-IP-MS with invasion and pathway assays in melanoma; cardiac-specific CASAAV Lztr1 knockdown mice with transcriptomics, Ca2+ handling, and apoptosis assays","pmids":["40885854","40967536"],"confidence":"Medium","gaps":["Direct substrates underlying these phenotypes not defined","Reconciliation of tumor-suppressive vs pro-invasive roles unresolved"]},{"year":null,"claim":"How LZTR1 integrates its many substrate axes—RAS/RIT1 degradation, RTK and CHMP1B turnover, KLHL12 repression, and ubiquitination-independent transcriptional/translational roles—into tissue-specific outputs, and how phosphorylation gating is structurally read out, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No high-resolution structure of substrate-bound CRL3-LZTR1","Hierarchy and competition among substrates across cell types unmapped","Mechanistic link between Golgi localization and ubiquitin ligase activity unestablished"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,3,8,12]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[1,2,4,12]},{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[1,3,12]}],"localization":[{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[0]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[8]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2,3,12]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,3,12]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[8]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,12,14,15]}],"complexes":["CRL3-LZTR1 (CUL3 RING E3 ligase)"],"partners":["CUL3","KRAS","HRAS","MRAS","RIT1","CHMP1B","EGFR","AXL"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8N653","full_name":"Leucine-zipper-like transcriptional regulator 1","aliases":[],"length_aa":840,"mass_kda":94.7,"function":"Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates ubiquitination of Ras (K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS) (PubMed:30442762, PubMed:30442766, PubMed:30481304). Is a negative regulator of RAS-MAPK signaling that acts by controlling Ras levels and decreasing Ras association with membranes (PubMed:30442762, PubMed:30442766, PubMed:30481304)","subcellular_location":"Endomembrane system; Recycling endosome; Golgi apparatus","url":"https://www.uniprot.org/uniprotkb/Q8N653/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LZTR1","classification":"Not Classified","n_dependent_lines":10,"n_total_lines":1208,"dependency_fraction":0.008278145695364239},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LZTR1","total_profiled":1310},"omim":[{"mim_id":"616564","title":"NOONAN SYNDROME 10; NS10","url":"https://www.omim.org/entry/616564"},{"mim_id":"616559","title":"NOONAN SYNDROME 9; NS9","url":"https://www.omim.org/entry/616559"},{"mim_id":"615670","title":"SCHWANNOMATOSIS 2; SWN2","url":"https://www.omim.org/entry/615670"},{"mim_id":"614647","title":"COENZYME Q6, MONOOXYGENASE; COQ6","url":"https://www.omim.org/entry/614647"},{"mim_id":"609591","title":"RIC-LIKE PROTEIN WITHOUT CAAX MOTIF 1; RIT1","url":"https://www.omim.org/entry/609591"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Centrosome","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/LZTR1"},"hgnc":{"alias_symbol":["LZTR-1","BTBD29"],"prev_symbol":[]},"alphafold":{"accession":"Q8N653","domains":[{"cath_id":"2.120.10.80","chopping":"52-332_384-419","consensus_level":"medium","plddt":88.7471,"start":52,"end":419},{"cath_id":"3.30.710.10","chopping":"427-487_507-632","consensus_level":"medium","plddt":88.9398,"start":427,"end":632},{"cath_id":"1.25.40","chopping":"770-840","consensus_level":"medium","plddt":84.1665,"start":770,"end":840}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N653","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N653-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N653-F1-predicted_aligned_error_v6.png","plddt_mean":80.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LZTR1","jax_strain_url":"https://www.jax.org/strain/search?query=LZTR1"},"sequence":{"accession":"Q8N653","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8N653.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8N653/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N653"}},"corpus_meta":[{"pmid":"24362817","id":"PMC_24362817","title":"Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas.","date":"2013","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24362817","citation_count":231,"is_preprint":false},{"pmid":"25795793","id":"PMC_25795793","title":"Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome.","date":"2015","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25795793","citation_count":196,"is_preprint":false},{"pmid":"30442766","id":"PMC_30442766","title":"LZTR1 is a regulator of RAS ubiquitination and signaling.","date":"2018","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/30442766","citation_count":182,"is_preprint":false},{"pmid":"30442762","id":"PMC_30442762","title":"Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination.","date":"2018","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/30442762","citation_count":171,"is_preprint":false},{"pmid":"29469822","id":"PMC_29469822","title":"Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants.","date":"2018","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29469822","citation_count":163,"is_preprint":false},{"pmid":"27856782","id":"PMC_27856782","title":"Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.","date":"2016","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27856782","citation_count":102,"is_preprint":false},{"pmid":"25480913","id":"PMC_25480913","title":"Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis.","date":"2014","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25480913","citation_count":97,"is_preprint":false},{"pmid":"31337872","id":"PMC_31337872","title":"LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases.","date":"2019","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/31337872","citation_count":92,"is_preprint":false},{"pmid":"30872527","id":"PMC_30872527","title":"RIT1 oncoproteins escape LZTR1-mediated proteolysis.","date":"2019","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/30872527","citation_count":90,"is_preprint":false},{"pmid":"30481304","id":"PMC_30481304","title":"Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30481304","citation_count":74,"is_preprint":false},{"pmid":"25335493","id":"PMC_25335493","title":"Expanding the mutational spectrum of LZTR1 in schwannomatosis.","date":"2014","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/25335493","citation_count":65,"is_preprint":false},{"pmid":"16356934","id":"PMC_16356934","title":"The BTB-kelch protein LZTR-1 is a novel Golgi protein that is degraded upon induction of apoptosis.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16356934","citation_count":63,"is_preprint":false},{"pmid":"30368668","id":"PMC_30368668","title":"Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes.","date":"2018","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30368668","citation_count":61,"is_preprint":false},{"pmid":"30859559","id":"PMC_30859559","title":"Delineation of dominant and recessive forms of LZTR1-associated Noonan syndrome.","date":"2019","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30859559","citation_count":51,"is_preprint":false},{"pmid":"32339168","id":"PMC_32339168","title":"Analysis of genes within the schizophrenia-linked 22q11.2 deletion identifies interaction of night owl/LZTR1 and NF1 in GABAergic sleep control.","date":"2020","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32339168","citation_count":30,"is_preprint":false},{"pmid":"31825158","id":"PMC_31825158","title":"Providing more evidence on LZTR1 variants in Noonan syndrome patients.","date":"2019","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/31825158","citation_count":28,"is_preprint":false},{"pmid":"34113392","id":"PMC_34113392","title":"LZTR1: A promising adaptor of the CUL3 family.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/34113392","citation_count":24,"is_preprint":false},{"pmid":"27472264","id":"PMC_27472264","title":"Multifocal nerve lesions and LZTR1 germline mutations in segmental schwannomatosis.","date":"2016","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27472264","citation_count":24,"is_preprint":false},{"pmid":"32175818","id":"PMC_32175818","title":"The Noonan Syndrome Gene Lztr1 Controls Cardiovascular Function by Regulating Vesicular Trafficking.","date":"2020","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/32175818","citation_count":21,"is_preprint":false},{"pmid":"30664951","id":"PMC_30664951","title":"Oligo-astrocytoma in LZTR1-related Noonan syndrome.","date":"2019","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30664951","citation_count":21,"is_preprint":false},{"pmid":"35467524","id":"PMC_35467524","title":"Cross-species analysis of LZTR1 loss-of-function mutants demonstrates dependency to RIT1 orthologs.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/35467524","citation_count":21,"is_preprint":false},{"pmid":"37626065","id":"PMC_37626065","title":"LZTR1 deficiency exerts high metastatic potential by enhancing sensitivity to EMT induction and controlling KLHL12-mediated collagen secretion.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37626065","citation_count":19,"is_preprint":false},{"pmid":"35840934","id":"PMC_35840934","title":"LZTR1 molecular genetic overlap with clinical implications for Noonan syndrome and schwannomatosis.","date":"2022","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/35840934","citation_count":18,"is_preprint":false},{"pmid":"36445254","id":"PMC_36445254","title":"LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL.","date":"2023","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/36445254","citation_count":18,"is_preprint":false},{"pmid":"31533111","id":"PMC_31533111","title":"LZTR1: Genotype Expansion in Noonan Syndrome.","date":"2019","source":"Hormone research in paediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/31533111","citation_count":18,"is_preprint":false},{"pmid":"39003740","id":"PMC_39003740","title":"Mutation-induced LZTR1 polymerization provokes cardiac pathology in recessive Noonan syndrome.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39003740","citation_count":13,"is_preprint":false},{"pmid":"32575496","id":"PMC_32575496","title":"Simultaneous Detection of NF1, SPRED1, LZTR1, and NF2 Gene Mutations by Targeted NGS in an Italian Cohort of Suspected NF1 Patients.","date":"2020","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/32575496","citation_count":13,"is_preprint":false},{"pmid":"28295212","id":"PMC_28295212","title":"Constitutional LZTR1 mutation presenting with a unilateral vestibular schwannoma in a teenager.","date":"2017","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28295212","citation_count":13,"is_preprint":false},{"pmid":"26848914","id":"PMC_26848914","title":"Unilateral vestibular schwannoma in a patient with schwannomatosis in the absence of LZTR1 mutation.","date":"2016","source":"Journal of neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/26848914","citation_count":13,"is_preprint":false},{"pmid":"34184824","id":"PMC_34184824","title":"Expanding the clinical phenotype of RASopathies in 38 Turkish patients, including the rare LZTR1, RAF1, RIT1 variants, and large deletion in NF1.","date":"2021","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/34184824","citation_count":12,"is_preprint":false},{"pmid":"35114566","id":"PMC_35114566","title":"The GSK3 kinase and LZTR1 protein regulate the stability of Ras family proteins and the proliferation of pancreatic cancer cells.","date":"2022","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35114566","citation_count":11,"is_preprint":false},{"pmid":"35656879","id":"PMC_35656879","title":"Molecular autopsy and clinical family screening in a case of sudden cardiac death reveals ACTN2 mutation related to hypertrophic/dilated cardiomyopathy and a novel LZTR1 variant associated with Noonan syndrome.","date":"2022","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35656879","citation_count":11,"is_preprint":false},{"pmid":"39352760","id":"PMC_39352760","title":"Dysregulation of RAS proteostasis by autosomal-dominant LZTR1 mutation induces Noonan syndrome-like phenotypes in mice.","date":"2024","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/39352760","citation_count":10,"is_preprint":false},{"pmid":"36304179","id":"PMC_36304179","title":"RASopathy Cohort of Patients Enrolled in a Brazilian Reference Center for Rare Diseases: A Novel Familial LZTR1 Variant and Recurrent Mutations.","date":"2022","source":"The application of clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36304179","citation_count":9,"is_preprint":false},{"pmid":"31883238","id":"PMC_31883238","title":"Noonan syndrome-associated biallelic LZTR1 mutations cause cardiac hypertrophy and vascular malformations in zebrafish.","date":"2019","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31883238","citation_count":9,"is_preprint":false},{"pmid":"31044557","id":"PMC_31044557","title":"Further support linking the 22q11.2 microduplication to an increased risk of bladder exstrophy and highlighting LZTR1 as a candidate gene.","date":"2019","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31044557","citation_count":8,"is_preprint":false},{"pmid":"38453365","id":"PMC_38453365","title":"Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex.","date":"2024","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/38453365","citation_count":6,"is_preprint":false},{"pmid":"33407364","id":"PMC_33407364","title":"A Chinese family with Noonan syndrome caused by a heterozygous variant in LZTR1: a case report and literature review.","date":"2021","source":"BMC endocrine disorders","url":"https://pubmed.ncbi.nlm.nih.gov/33407364","citation_count":6,"is_preprint":false},{"pmid":"39062695","id":"PMC_39062695","title":"Phenotypic Expansion of Autosomal Dominant LZTR1-Related Disorders with Special Emphasis on Adult-Onset Features.","date":"2024","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/39062695","citation_count":5,"is_preprint":false},{"pmid":"38333672","id":"PMC_38333672","title":"Preclinical evaluation of CRISPR-based therapies for Noonan syndrome caused by deep-intronic LZTR1 variants.","date":"2024","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/38333672","citation_count":5,"is_preprint":false},{"pmid":"33792302","id":"PMC_33792302","title":"Structural Model for Recruitment of RIT1 to the LZTR1 E3 Ligase: Evidences from an Integrated Computational Approach.","date":"2021","source":"Journal of chemical information and modeling","url":"https://pubmed.ncbi.nlm.nih.gov/33792302","citation_count":5,"is_preprint":false},{"pmid":"33269527","id":"PMC_33269527","title":"LZTR1-related spinal schwannomatosis and 7q11.23 duplication syndrome: A complex phenotype with dual diagnosis.","date":"2020","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33269527","citation_count":5,"is_preprint":false},{"pmid":"39140257","id":"PMC_39140257","title":"Heterozygosity for loss-of-function variants in LZTR1 is associated with isolated multiple café-au-lait macules.","date":"2024","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39140257","citation_count":4,"is_preprint":false},{"pmid":"39194017","id":"PMC_39194017","title":"Identification and Characterization of Novel Small-Molecule Enhancers of the CUL3LZTR1 E3 Ligase KRAS Complex.","date":"2024","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/39194017","citation_count":4,"is_preprint":false},{"pmid":"40295009","id":"PMC_40295009","title":"Pathogenic Variants and Allele Loss of the NF2 and LZTR1 Gene in Sporadic Vestibular Schwannoma.","date":"2025","source":"In vivo (Athens, Greece)","url":"https://pubmed.ncbi.nlm.nih.gov/40295009","citation_count":4,"is_preprint":false},{"pmid":"38689733","id":"PMC_38689733","title":"Gonadal dysfunction in a man with Noonan syndrome from the LZTR1 variant: case report and review of literature.","date":"2024","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/38689733","citation_count":3,"is_preprint":false},{"pmid":"36304963","id":"PMC_36304963","title":"A Comprehensive Pan-Cancer Analysis of the Tumorigenic Effect of Leucine-Zipper-Like Transcription Regulator (LZTR1) in Human Cancer.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/36304963","citation_count":3,"is_preprint":false},{"pmid":"34913528","id":"PMC_34913528","title":"Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.","date":"2021","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/34913528","citation_count":3,"is_preprint":false},{"pmid":"40114953","id":"PMC_40114953","title":"Novel LZTR1 germline mutation as a mechanism of resistance to osimertinib in EGFR-mutated lung adenocarcinoma: a case report.","date":"2025","source":"Translational lung cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/40114953","citation_count":3,"is_preprint":false},{"pmid":"40885854","id":"PMC_40885854","title":"LZTR1 is a melanoma oncogene that promotes invasion and suppresses apoptosis.","date":"2025","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/40885854","citation_count":2,"is_preprint":false},{"pmid":"39258154","id":"PMC_39258154","title":"LZTR1 loss-of-function variants associated with café au lait macules with or without freckling.","date":"2024","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/39258154","citation_count":1,"is_preprint":false},{"pmid":"41162356","id":"PMC_41162356","title":"LZTR1 regulates epithelial MHC-I expression via NF-κB1 to modulate CD8+ T cells activation.","date":"2025","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/41162356","citation_count":1,"is_preprint":false},{"pmid":"40967536","id":"PMC_40967536","title":"Lztr1 deficiency contributes to the pathogenesis of dilated cardiomyopathy via RAP1/PI3K/AKT-mediated myocardial Injury.","date":"2025","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/40967536","citation_count":1,"is_preprint":false},{"pmid":"40542439","id":"PMC_40542439","title":"LZTR1 expression as a novel predictive biomarker for early recurrence of hepatocellular carcinoma.","date":"2025","source":"European journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/40542439","citation_count":1,"is_preprint":false},{"pmid":"37509153","id":"PMC_37509153","title":"Exome Survey and Candidate Gene Re-Sequencing Identifies Novel Exstrophy Candidate Genes and Implicates LZTR1 in Disease Formation.","date":"2023","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/37509153","citation_count":1,"is_preprint":false},{"pmid":"34222248","id":"PMC_34222248","title":"Generation of a Mouse Model to Study the Noonan Syndrome Gene Lztr1 in the Telencephalon.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34222248","citation_count":1,"is_preprint":false},{"pmid":"39577308","id":"PMC_39577308","title":"Generation of a human induced pluripotent stem cell line from a female patient carrying LZTR1 gene mutation.","date":"2024","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/39577308","citation_count":1,"is_preprint":false},{"pmid":"40724954","id":"PMC_40724954","title":"LZTR1: c.1260+1del Variant as a Significant Predictor of Early-Age Breast Cancer Development: Case Report Combined with In Silico Analysis.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40724954","citation_count":1,"is_preprint":false},{"pmid":"34401172","id":"PMC_34401172","title":"Spontaneous resolution of nonimmune hydrops fetalis in a fetus with TP63 gene mutation and LZTR1 gene variants.","date":"2021","source":"Clinical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/34401172","citation_count":1,"is_preprint":false},{"pmid":"40204202","id":"PMC_40204202","title":"The tumor suppressor LZTR1: Its expression, purification and characterization.","date":"2025","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/40204202","citation_count":0,"is_preprint":false},{"pmid":"41286185","id":"PMC_41286185","title":"Novel susceptibility genes for non-NF2-/LZTR1-/SMARCB1-related hereditary schwannomatosis.","date":"2025","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/41286185","citation_count":0,"is_preprint":false},{"pmid":"41752002","id":"PMC_41752002","title":"LZTR1 Loss Reduces Vimentin Expression and Motility in Hep3B Hepatocellular Carcinoma Cells.","date":"2026","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41752002","citation_count":0,"is_preprint":false},{"pmid":"40803040","id":"PMC_40803040","title":"Genetic Variants in LZTR1, MAP2K1 and RAF1: Insights into the Role of RAS-MAPK Pathway in Primary Lymphedema.","date":"2025","source":"Lymphology","url":"https://pubmed.ncbi.nlm.nih.gov/40803040","citation_count":0,"is_preprint":false},{"pmid":"40521264","id":"PMC_40521264","title":"Protein-losing enteropathy and multiple vasculature dysplasia in LZTR1-related Noonan syndrome: A case report and review of literature.","date":"2025","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/40521264","citation_count":0,"is_preprint":false},{"pmid":"38983105","id":"PMC_38983105","title":"Familial schwannomatosis carrying LZTR1 variant p.R340X with brain tumor: A case report.","date":"2024","source":"Molecular genetics and metabolism reports","url":"https://pubmed.ncbi.nlm.nih.gov/38983105","citation_count":0,"is_preprint":false},{"pmid":"41175093","id":"PMC_41175093","title":"Pathogenesis of Noonan Syndrome is Modulated by NOC2L, a Novel Interactor of LZTR1 Leading to Impaired P53 Signalling.","date":"2026","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/41175093","citation_count":0,"is_preprint":false},{"pmid":"41542462","id":"PMC_41542462","title":"Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41542462","citation_count":0,"is_preprint":false},{"pmid":"41522855","id":"PMC_41522855","title":"Central nervous system schwannoma, VGLL-fused (EWSR1::VGLL1 fusion) with neuroblastoma-like cell dense areas in the frontal lobe of a young man with schwannomatosis due to a germline LZTR1 mutation.","date":"2026","source":"Free neuropathology","url":"https://pubmed.ncbi.nlm.nih.gov/41522855","citation_count":0,"is_preprint":false},{"pmid":"41196194","id":"PMC_41196194","title":"Homozygous LZTR1 Variant Lacking the Second BTB Domain Associated With Bone Marrow Failure and Multiple Congenital Anomalies Distinct From Those of Noonan Syndrome.","date":"2025","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41196194","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.12.03.24317221","title":"Assessing the diagnostic impact of blood transcriptome profiling in a pediatric cohort previously assessed by genome sequencing","date":"2024-12-05","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.03.24317221","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":35378,"output_tokens":7621,"usd":0.110225,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16837,"output_tokens":5967,"usd":0.11668,"stage2_stop_reason":"end_turn"},"total_usd":0.226905,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"LZTR1 (LZTR-1) localizes exclusively to the cytoplasmic surface of the Golgi network, with this localization mediated by its second BTB/POZ domain. Treatment with brefeldin A causes LZTR1 to redistribute into dispersed punctuated structures that co-localize with the Golgi marker GM130, identifying it as a Golgi matrix-associated protein. Upon induction of apoptosis, LZTR1 is phosphorylated on tyrosine residues and subsequently degraded via caspase- and proteasome-dependent pathways.\",\n      \"method\": \"Confocal microscopy with Golgi markers (GM130, Golgin-97, TGN46), brefeldin A treatment, co-localization with actin, caspase inhibitor (Z-VAD-fmk) and proteasome inhibitor (lactacystin, MG132) rescue experiments, domain-deletion analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiments with functional consequence (apoptosis-linked degradation), multiple orthogonal methods, single lab\",\n      \"pmids\": [\"16356934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LZTR1 functions as a CUL3 (cullin 3) ubiquitin ligase adaptor that ubiquitinates RAS GTPases (KRAS, HRAS, NRAS, MRAS) at lysine-170 (HRAS) and lysine-127 (MRAS). LZTR1-mediated ubiquitination at K170 inhibits RAS signaling by attenuating RAS association with the plasma membrane. Disease-associated LZTR1 mutations disrupt either LZTR1-CUL3 complex formation or LZTR1 interaction with RAS proteins.\",\n      \"method\": \"LZTR1 complex trapping from intact mammalian cells, ubiquitome mass spectrometry analysis, site-directed mutagenesis (K170 on HRAS, K127 on MRAS), membrane localization assays, mouse haploinsufficiency model recapitulating Noonan syndrome phenotypes, Schwann cell knockout driving dedifferentiation and proliferation\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — reconstitution-level trapping, ubiquitome MS with site-specific mutagenesis, in vivo mouse model, replicated independently in same issue by Bigenzahn et al.\",\n      \"pmids\": [\"30442762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Inactivation of LZTR1 (the CUL3 adaptor) in human CML cells leads to enhanced MAPK pathway activity and reduced sensitivity to tyrosine kinase inhibitors. Endogenous human LZTR1 associates with the main RAS isoforms. LZTR1 inactivation causes decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS. Knockdown of the Drosophila LZTR1 ortholog CG3711 results in a Ras-dependent gain-of-function phenotype.\",\n      \"method\": \"Genetic screens in CML cells, siRNA knockdown in human cells, co-immunoprecipitation of endogenous LZTR1 with RAS isoforms, membrane localization assays, Drosophila CG3711 knockdown with genetic epistasis\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP of endogenous proteins, genetic epistasis in Drosophila, functional phenotype in human cells, independently corroborated by Steklov et al. in same issue\",\n      \"pmids\": [\"30442766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LZTR1 promotes polyubiquitination and proteasomal degradation of RAS GTPases (HRAS, NRAS, KRAS, MRAS), including oncogenic RAS mutants, via ubiquitin chains containing K48, K63, and K33 linkages. MRAS-K127 and HRAS-K170 are ubiquitination sites. LZTR1-mediated RAS degradation inhibits ERK1/2 activation and cell growth. LZTR1 also interacts with autophagy proteins LC3B and SQSTM1/p62, and co-expression of LZTR1 and RAS increases lipidated LC3B, but long-term chloroquine treatment has minimal effect on RAS levels, indicating autophagy plays a minor role compared to proteasomal degradation.\",\n      \"method\": \"In vivo ubiquitination assays, immunoprecipitation, western blotting, site-directed mutagenesis of ubiquitination sites, chloroquine treatment, LC3B lipidation assay, ERK1/2 activation assays, cell proliferation assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vivo ubiquitination assays with site-specific mutagenesis, multiple RAS isoforms tested, multiple orthogonal methods, independently corroborates Steklov et al. findings\",\n      \"pmids\": [\"31337872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LZTR1 acts as an adaptor for proteasomal degradation of the RAS GTPase RIT1. Pathogenic mutations in either RIT1 (near switch II domain) or LZTR1 result in incomplete degradation of RIT1, causing RIT1 accumulation and dysregulated growth factor signaling. LZTR1 was identified as a RIT1 interactor by mass spectrometry.\",\n      \"method\": \"Mass spectrometry identification of RIT1-LZTR1 interaction, isogenic germline knock-in mouse model (RIT1 mutation), functional degradation assays, growth factor signaling readouts\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — MS identification confirmed with functional in vivo mouse model, mechanistic degradation assays, multiple orthogonal approaches\",\n      \"pmids\": [\"30872527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Dominant Noonan syndrome-causing LZTR1 mutations do not disrupt binding to CUL3 but are predicted to affect the Kelch domain surface mediating substrate binding. These dominant mutations enhance stimulus-dependent RAS-MAPK signaling, at least partly by increasing the RAS protein pool. Dominant NS mutations do not affect LZTR1 protein stability or subcellular localization, unlike missense changes occurring in recessive NS.\",\n      \"method\": \"Transfection of NS-associated LZTR1 mutants, MAPK pathway activation assays (phospho-ERK), RAS protein level measurements, co-immunoprecipitation with CUL3, subcellular localization analysis, protein stability assays, structural modeling of Kelch domain\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays in cell lines, Co-IP with CUL3, single lab, no in vivo validation\",\n      \"pmids\": [\"30481304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LZTR1 binds to the RAF1-PPP1CB complex as detected by immunoprecipitation of endogenous LZTR1. Cells transfected with siRNA against LZTR1 show decreased levels of RAF1 phosphorylated at Ser259, indicating LZTR1 modulates RAF1 phosphorylation status within the RAS/MAPK pathway.\",\n      \"method\": \"Endogenous co-immunoprecipitation followed by western blotting, siRNA knockdown of LZTR1, phospho-RAF1 (Ser259) western blotting\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — reciprocal endogenous Co-IP and functional knockdown result, single lab, two orthogonal methods\",\n      \"pmids\": [\"30368668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LZTR1 (night owl/nowl) negatively regulates Ras signaling and interacts genetically with Neurofibromin-1 (Nf1) in the control of night-time sleep in Drosophila. Knockdown of nowl or Nf1 in GABA-responsive sleep-promoting neurons elicits a sleep phenotype that can be rescued by increased GABAA receptor signaling, indicating Nowl regulates sleep through modulation of GABA signaling. Nowl is also required for metabolic homeostasis.\",\n      \"method\": \"Drosophila genetic loss-of-function (nowl knockdown), genetic epistasis with Nf1 mutants, tissue-specific knockdown in GABAergic neurons, GABAA receptor pharmacological rescue, sleep behavior quantification, metabolic assays\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with defined cellular phenotype in Drosophila model, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"32339168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LZTR1 controls cardiovascular function by regulating vesicular trafficking. LZTR1 affects dynamics of fusion and fission of recycling endosomes by controlling ubiquitination of the ESCRT-III component CHMP1B (charged multivesicular protein 1B). NS-associated LZTR1 mutations diminish CHMP1B ubiquitination. LZTR1-mediated dysregulation of CHMP1B ubiquitination triggers endosomal accumulation and subsequent activation of VEGFR2, and decreases blood levels of soluble VEGFR2. Whole-body and vascular-specific Lztr1 knockout causes perinatal lethality from cardiovascular dysfunction; Lztr1 deletion in adult blood vessels leads to abnormal vascular leakage with defective adherent and tight junctions due to dysregulated vesicular trafficking.\",\n      \"method\": \"Conditional and whole-body Lztr1 knockout mice, endothelial-specific knockout, vascular permeability assays, endosomal trafficking assays, ubiquitination assays for CHMP1B, VEGFR2 activity measurements, ELISA for soluble VEGFR2, cediranib (VEGFR2 inhibitor) rescue experiments\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vivo knockout models with defined vascular phenotype, ubiquitination assays identifying novel substrate CHMP1B, rescue with VEGFR2 inhibitor, multiple orthogonal methods\",\n      \"pmids\": [\"32175818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In both fruit flies and mice, LZTR1 shows a biochemical preference for RIT1 orthologs over classical RAS GTPases. Embryonic lethality of homozygous Lztr1 null mice can be rescued by deletion of Rit1, demonstrating genetic epistasis and establishing RIT1 orthologs as the preferred in vivo substrates of LZTR1.\",\n      \"method\": \"Lztr1 loss-of-function mutants in Drosophila and mice, Rit1 knockout rescue of Lztr1 null lethality, biochemical substrate preference assays, genetic epistasis analysis\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — cross-species genetic epistasis with defined rescue of lethal phenotype, biochemical substrate preference, multiple organisms\",\n      \"pmids\": [\"35467524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LZTR1 deficiency increases accumulation of RAS subfamily members and enhances cell proliferation, invasion, and xenograft tumor growth. LZTR1 inhibits KLHL12-mediated ubiquitination of SEC31A (a COPII component), and LZTR1 deficiency promotes collagen secretion via KLHL12. LZTR1-RIT1 and LZTR1-KLHL12 interactions are independent and do not directly interfere with each other. LZTR1 functions as a repressor of BTB-Kelch family member KLHL12.\",\n      \"method\": \"LZTR1 knockout in lung adenocarcinoma cells, multi-omics analysis, co-immunoprecipitation identifying KLHL12 interaction, SEC31A ubiquitination assays, collagen secretion assays, xenograft tumor growth assays, EMT marker analysis under TGF-β1 treatment\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP identifying novel substrate KLHL12 with functional ubiquitination assays and collagen secretion readout, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"37626065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GSK3 regulates LZTR1 function: inhibiting or silencing GSK3 in pancreatic cancer cells leads to a decline in Ras protein levels (wild-type and oncogenic KRAS) via a 3-fold decrease in Ras protein half-life. This decline is blocked by proteasome inhibition or LZTR1 knockdown, establishing a GSK3-regulated LZTR1-dependent mechanism controlling Ras protein stability and cell proliferation.\",\n      \"method\": \"GSK3 inhibitor treatment and siRNA knockdown in pancreatic cancer cells, LZTR1 siRNA knockdown, protein half-life measurements, proteasome inhibition rescue, cell proliferation assays\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis via double knockdown (GSK3 + LZTR1), half-life measurements, proteasome rescue, single lab\",\n      \"pmids\": [\"35114566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"LZTR1 is the substrate-specific adaptor of a CUL3-dependent ubiquitin ligase that targets EGFR and AXL receptor tyrosine kinases for ubiquitin-dependent degradation in the lysosome. Pathogenic cancer-associated LZTR1 mutations fail to promote EGFR and AXL degradation, resulting in dysregulated growth factor signaling. Conditional inactivation of Lztr1 and Cdkn2a in the mouse nervous system causes schwannoma-like tumors with aberrant accumulation of EGFR and AXL.\",\n      \"method\": \"Unbiased biochemical screens (Co-IP/MS) identifying EGFR and AXL as LZTR1 interactors, ubiquitination and degradation assays, lysosomal pathway determination, Lztr1/Cdkn2a conditional mouse knockout, EGFR+AXL co-inhibition in tumor models\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — unbiased screen followed by biochemical validation, in vivo mouse model, mechanistic degradation assays identifying lysosomal pathway, multiple orthogonal methods\",\n      \"pmids\": [\"36445254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Oncogenic KRAS mutations G12D, G13D, and Q61H abrogate KRAS association with LZTR1, thereby affecting KRAS turnover by the CUL3/LZTR1 E3 ligase complex. Wild-type KRAS but not oncogenic mutants are efficiently captured by LZTR1.\",\n      \"method\": \"APEX2 proximity labeling of WT, G12D, G13D, and Q61H KRAS mutants, quantitative proteomics under starvation and stimulation conditions, differential LZTR1 capture analysis\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proximity labeling proteomics with multiple KRAS mutants compared, single lab, no direct ubiquitination assay in abstract\",\n      \"pmids\": [\"38453365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A homozygous LZTR1 L580P variant is predicted to alter binding affinity of dimerization domains, facilitating formation of linear LZTR1 polymers. This complex dysfunction results in accumulation of RAS GTPases and global pathological proteomic changes leading to cardiomyocyte hypertrophy. Cardiomyocyte-specific MRAS degradation is mediated by LZTR1 via non-proteasomal pathways, whereas RIT1 degradation is mediated by both LZTR1-dependent and LZTR1-independent pathways. Biallelic genetic correction of LZTR1 L580P rescues the molecular and cellular disease phenotype.\",\n      \"method\": \"Patient-specific and CRISPR-Cas9-corrected iPSC-derived cardiomyocytes, in silico polymer formation prediction, proteomics, RAS accumulation assays, CRISPR rescue experiments, pathway inhibitor studies\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — iPSC patient model with CRISPR correction (rescue), proteomics, functional hypertrophy readout, single lab\",\n      \"pmids\": [\"39003740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LZTR1 autosomal dominant mutations (G245R and R409C, corresponding to human G248R and R412C) cause dominant-negative inhibition of wild-type LZTR1 function. These mutants do not interact with RIT1 and result in accumulation of MRAS and RIT1 in cardiomyocytes, activating the MAPK signaling pathway. MEK inhibitor trametinib treatment ameliorates cardiac hypertrophy in mutant mice.\",\n      \"method\": \"LZTR1 knock-in mice (Lztr1G245R/+ and Lztr1R409C/+), co-immunoprecipitation with RIT1, MRAS and RIT1 protein level assays in left ventricles, multi-omics analysis, trametinib treatment rescue\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knock-in mouse model with dominant-negative mechanism established by Co-IP and protein level assays, pharmacological rescue, single lab\",\n      \"pmids\": [\"39352760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Novel small-molecule fragments (C53 and Z86) enhance the KRAS-LZTR1 protein-protein interaction in a dose-dependent manner, as shown by split-luciferase reporter assay, proximity biotinylation (BioID), thermal shift assays, and NMR spectroscopy. These fragments increase endogenous LZTR1 recruitment to KRAS.\",\n      \"method\": \"Split-luciferase-based reporter assay for KRAS-LZTR1 interaction, fragment library screen, BioID proximity biotinylation, thermal shift assays, NMR spectroscopy\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal biophysical and cell-based methods validating PPI enhancement, single lab, no in vivo validation\",\n      \"pmids\": [\"39194017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PP1C phosphatase dephosphorylates the conserved T148 residue on RAS, which permits LZTR1-dependent proteasomal degradation. Phosphorylation of RAS T148 by PAK1/2 kinases shields RAS from LZTR1-dependent degradation. KRAS A146 gain-of-function mutations (adjacent to T148) render LZTR1 ineffective at promoting degradation. KRAS protein is four-fold less stable in hematologic versus carcinoma cells due to this regulatory circuit.\",\n      \"method\": \"Multi-omics screening in multiple myeloma cells, phosphatase identification (PP1C), kinase identification (PAK1/2), T148 mutagenesis, LZTR1-dependent degradation assays, PAK1/2 inhibitor treatment, protein stability measurements\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mechanistic dissection with site-specific mutagenesis and writer/eraser identification, multi-omics screen, preprint not yet peer-reviewed\",\n      \"pmids\": [\"41542462\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"LZTR1 regulates MHC-I expression in epithelial cells through an NF-κB1-dependent mechanism. Mechanistically, LZTR1 modulates MHC-I transcription by regulating co-translational biogenesis of NF-κB1 (p50) in a ubiquitination-independent but proteasome-dependent manner through direct binding with ribosome and proteasome. Loss of LZTR1 leads to suppression of CD8+ TRM activation and proliferation and decreased IL-17A production.\",\n      \"method\": \"LZTR1 knockout in cutaneous and colonic epithelial cells/organoids, NF-κB1 (p50) processing assays, ribosome and proteasome co-immunoprecipitation, MHC-I expression assays, in vivo CD8+ TRM functional readouts\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding assays with ribosome/proteasome, functional in vivo readout, ubiquitination-independent mechanism established, single lab\",\n      \"pmids\": [\"41162356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"LZTR1 interacts with NOC2L (a histone acetyltransferase inhibitor), and this interaction is disrupted by dominant Noonan syndrome LZTR1 variants. Loss of LZTR1-NOC2L interaction leads to NOC2L upregulation, impaired p53 acetylation, reduced apoptosis, and compensatory increase in autophagy. LZTR1 variants are thermodynamically stable in vitro and associated with elevated pan-RAS levels and preferential activation of the DNA damage response.\",\n      \"method\": \"Mutagenesis of LZTR1 variants, phosphoproteomics, immunoblotting, immunofluorescence, nanoluciferase assays (PPI), in silico structural modeling, p53 acetylation assays, LC3 and phospho-p70 S6K measurements\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — nanoluciferase PPI assay plus phosphoproteomics and functional downstream readouts, single lab, interaction not yet independently replicated\",\n      \"pmids\": [\"41175093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"LZTR1 overexpression in melanoma activates ERBB3 receptor and its downstream targets PYK2 and SRC tyrosine kinases, enhancing cell invasion and actin cytoskeleton organization. LZTR1 associates with actin-related proteins. LZTR1 downregulation suppresses the protective autophagy-initiating factors ULK1 and AMBRA1, and upregulates SQSTM1/p62. LZTR1 regulates the ubiquitin proteasome system in melanoma cells.\",\n      \"method\": \"Proximity biotinylation and co-immunoprecipitation combined with LC-MS/MS proteomics, LZTR1 knockdown/overexpression in melanoma cells, invasion assays, ERBB3/PYK2/SRC pathway activation assays, autophagy marker measurements\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — BioID + Co-IP proteomics with functional pathway validation, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"40885854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In a cardiac-specific Lztr1 knockdown mouse model, Lztr1 deficiency activates the RAP1/MAPK/AKT signaling pathway leading to Ca2+ homeostasis disorder and cardiomyocyte apoptosis, recapitulating dilated cardiomyopathy pathology. The transcriptomic analysis identified the RAP1 pathway as a key downstream effector.\",\n      \"method\": \"CRISPR-Cas9/AAV9-mediated cardiac-specific Lztr1 knockdown (CASAAV system), cardiac function assays, transcriptomic sequencing, pathway analysis, mitochondrial and Ca2+ handling assays, apoptosis assays\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo cardiac-specific KO with transcriptomic pathway identification and functional readouts, single lab\",\n      \"pmids\": [\"40967536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Full-length CRL3LZTR1-MRAS complex was successfully expressed and purified. MRAS binds tightly to LZTR1, in contrast to RIT1 and HRAS under these in vitro conditions. The presence of CRL3 (Cullin3 RING ligase) stabilizes and homogenizes LZTR1 by facilitating complex formation.\",\n      \"method\": \"BacMam expression system, protein purification and biochemical characterization, in vitro binding assays comparing MRAS, RIT1, and HRAS binding to LZTR1\",\n      \"journal\": \"Protein expression and purification\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct in vitro reconstitution and binding assay, but single lab and limited functional follow-up in abstract\",\n      \"pmids\": [\"40204202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Conditional knockout of Lztr1 restricted to the telencephalon results in increased MAPK pathway activation in white matter regions, altered expression of stage-specific oligodendrocyte lineage markers with increased oligodendrocyte progenitor cells (OPCs) and decreased oligodendrocyte differentiation markers, and increased GFAP astrocyte marker expression.\",\n      \"method\": \"Foxg1-Cre conditional Lztr1 knockout mice, immunohistochemistry for oligodendrocyte lineage markers, GFAP staining, MAPK pathway activation assays (phospho-ERK), quantitative analysis of OPC and mature oligodendrocyte markers\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined cellular phenotype (oligodendrocyte differentiation block), MAPK activation measured, single lab\",\n      \"pmids\": [\"34222248\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LZTR1 is a BTB-Kelch domain adaptor protein that associates with CUL3 (cullin 3) to form a RING E3 ubiquitin ligase complex, which ubiquitinates RAS GTPases (KRAS, HRAS, NRAS, MRAS, and especially RIT1) at conserved lysine residues (e.g., K170 on HRAS), promoting their proteasomal degradation and attenuating their membrane association and MAPK signaling; LZTR1 also ubiquitinates EGFR, AXL, and CHMP1B (for endosomal trafficking control), and regulates RAS stability through a GSK3-dependent and PAK1/2-T148 phosphorylation-governed circuit, while disease-associated mutations disrupt substrate binding, CUL3 interaction, or LZTR1 dimerization, collectively causing accumulation of RAS GTPases and hyperactivation of MAPK signaling that underlies schwannomatosis, Noonan syndrome, and various cancers.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"LZTR1 is a BTB-Kelch substrate-specific adaptor for a CUL3 RING E3 ubiquitin ligase that restrains RAS-MAPK signaling by targeting RAS-family GTPases for ubiquitin-dependent degradation [#1, #2]. As the adaptor of the CRL3-LZTR1 complex, it ubiquitinates KRAS, HRAS, NRAS, and MRAS at conserved lysines (HRAS K170, MRAS K127), promoting their proteasomal turnover, attenuating their plasma-membrane association, and thereby dampening ERK1/2 activation and proliferation [#1, #3]; in vivo across flies and mice, RIT1 emerges as the genetically preferred substrate, since deletion of Rit1 rescues the lethality of Lztr1 loss [#4, #9]. Substrate engagement is gated by the GTPase nucleotide/mutational state and by post-translational marks: oncogenic KRAS mutations (G12D, G13D, Q61H, A146) abrogate LZTR1 capture and turnover [#13, #17], while a PAK1/2-phosphorylated/PP1C-dephosphorylated T148 switch and a GSK3-dependent input control RAS stability through LZTR1 [#11, #17]. Beyond RAS, LZTR1 directs CUL3-dependent lysosomal degradation of the receptor tyrosine kinases EGFR and AXL [#12] and controls vesicular trafficking by ubiquitinating the ESCRT-III component CHMP1B to regulate recycling-endosome dynamics and VEGFR2 signaling [#8]. Disease-associated mutations act through distinct mechanisms—disrupting substrate binding at the Kelch surface, CUL3 interaction, or LZTR1 dimerization—and dominant-negative variants poison wild-type LZTR1, causing accumulation of RAS/RIT1/MRAS and MAPK hyperactivation that underlies Noonan syndrome, schwannomatosis-like tumors, and cardiomyopathy, with MEK inhibition (trametinib) reversing cardiac phenotypes in mutant mice [#5, #12, #14, #15]. LZTR1 localizes to the cytoplasmic face of the Golgi via its second BTB domain [#0].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established the first cellular context for LZTR1, defining where it resides before any enzymatic role was known.\",\n      \"evidence\": \"Confocal microscopy with Golgi markers, brefeldin A, and domain-deletion analysis in mammalian cells\",\n      \"pmids\": [\"16356934\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No molecular activity assigned at this stage\", \"Functional consequence of Golgi localization for later-defined substrates unresolved\", \"Tyrosine-phosphorylation/caspase degradation pathway not connected to ubiquitin ligase function\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved the core biochemical function: LZTR1 is a CUL3 adaptor that ubiquitinates RAS GTPases at defined lysines to limit membrane association and MAPK output.\",\n      \"evidence\": \"Complex trapping, ubiquitome MS, site-directed mutagenesis (HRAS K170, MRAS K127), membrane-localization assays, and mouse haploinsufficiency model; corroborated by genetic screens and endogenous reciprocal Co-IP plus Drosophila epistasis\",\n      \"pmids\": [\"30442762\", \"30442766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitin chain linkage composition not yet defined\", \"Relative ranking of RAS isoform substrates in vivo unresolved\", \"Endosomal/RTK substrates not yet known\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connected LZTR1 to RAF1 phosphorylation, indicating it modulates signaling at additional nodes of the RAS/MAPK cascade.\",\n      \"evidence\": \"Endogenous Co-IP of LZTR1 with RAF1-PPP1CB and siRNA knockdown with phospho-RAF1 (Ser259) immunoblot\",\n      \"pmids\": [\"30368668\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect effect on RAF1 phosphorylation not distinguished\", \"No ubiquitination of RAF1 demonstrated\", \"Single lab, two methods\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined the degradation route and chain chemistry and identified RIT1 as a substrate, broadening the GTPase repertoire LZTR1 controls.\",\n      \"evidence\": \"In vivo ubiquitination assays with K48/K63/K33 linkage and site mutagenesis; MS identification of RIT1 interaction with isogenic knock-in mouse model\",\n      \"pmids\": [\"31337872\", \"30872527\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Autophagy contribution minor but not fully delineated\", \"Why RIT1 vs classical RAS preference unresolved at this stage\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Distinguished dominant from recessive disease mechanisms, showing dominant Noonan mutations spare CUL3 binding and stability but impair substrate recognition.\",\n      \"evidence\": \"Transfection of NS-associated mutants with phospho-ERK, RAS level, CUL3 Co-IP, stability/localization assays, and Kelch-domain modeling\",\n      \"pmids\": [\"30481304\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vivo validation\", \"Structural modeling not experimentally confirmed\", \"Mechanism of dominant effect not fully resolved here\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extended LZTR1 substrate scope beyond RAS to CHMP1B, linking it to endosomal trafficking and cardiovascular VEGFR2 control.\",\n      \"evidence\": \"Conditional/whole-body and endothelial Lztr1 knockout mice, CHMP1B ubiquitination assays, VEGFR2 readouts, and cediranib rescue\",\n      \"pmids\": [\"32175818\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relationship between RAS and CHMP1B substrate pathways unresolved\", \"Structural basis of CHMP1B recognition unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated conserved organismal physiology for LZTR1 RAS regulation, linking it to NF1 and GABAergic sleep control.\",\n      \"evidence\": \"Drosophila nowl loss-of-function, genetic epistasis with Nf1, tissue-specific knockdown, and GABAA pharmacological rescue\",\n      \"pmids\": [\"32339168\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mammalian relevance of sleep phenotype untested\", \"Direct substrate driving phenotype not identified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed LZTR1 loss perturbs CNS cell-fate decisions through MAPK hyperactivation, relevant to its tumor and developmental phenotypes.\",\n      \"evidence\": \"Foxg1-Cre conditional Lztr1 knockout mice with oligodendrocyte lineage marker analysis and phospho-ERK measurement\",\n      \"pmids\": [\"34222248\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Substrate driving lineage block not identified\", \"Single lab descriptive phenotype\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established RIT1 orthologs as the genetically preferred in vivo substrate by rescuing lethality, ranking substrates physiologically.\",\n      \"evidence\": \"Lztr1 loss-of-function in fly and mouse with Rit1 knockout rescue and biochemical substrate-preference assays\",\n      \"pmids\": [\"35467524\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biochemical basis of RIT1 preference vs classical RAS unresolved\", \"Tissue-specific substrate hierarchy not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified additional non-RAS roles—repression of KLHL12/SEC31A-mediated collagen secretion and a GSK3-dependent input controlling RAS stability.\",\n      \"evidence\": \"LZTR1 knockout in lung adenocarcinoma cells with KLHL12 Co-IP and SEC31A ubiquitination assays; GSK3 inhibition/knockdown with LZTR1-dependent half-life and proteasome-rescue assays in pancreatic cancer cells\",\n      \"pmids\": [\"37626065\", \"35114566\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which GSK3 acts on the LZTR1-RAS axis undefined\", \"KLHL12 repression mechanism single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Expanded substrate scope to receptor tyrosine kinases, showing LZTR1 routes EGFR and AXL to lysosomal degradation and that cancer mutations fail to do so.\",\n      \"evidence\": \"Unbiased Co-IP/MS, ubiquitination/degradation and lysosomal-pathway assays, and Lztr1/Cdkn2a conditional schwannoma mouse model with EGFR+AXL co-inhibition\",\n      \"pmids\": [\"36445254\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why these substrates go to lysosome vs proteasome unresolved\", \"CUL3-dependence of RTK degradation step not fully dissected\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed substrate capture is gated by KRAS mutational state, explaining how oncogenic mutants evade LZTR1-mediated turnover.\",\n      \"evidence\": \"APEX2 proximity labeling and quantitative proteomics comparing WT and G12D/G13D/Q61H KRAS under starvation/stimulation\",\n      \"pmids\": [\"38453365\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct ubiquitination assay for the mutants in this study\", \"Structural basis of impaired capture not shown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined two distinct disease-mutation mechanisms—dimerization-disrupting polymer formation and dominant-negative inhibition—both causing RAS/RIT1/MRAS accumulation and reversible by MEK inhibition.\",\n      \"evidence\": \"Patient/CRISPR-corrected iPSC cardiomyocytes with proteomics and rescue (L580P); Lztr1 G245R/R409C knock-in mice with RIT1 Co-IP, protein-level assays, and trametinib rescue\",\n      \"pmids\": [\"39003740\", \"39352760\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Polymer-formation model partly in silico\", \"Non-proteasomal MRAS degradation route in cardiomyocytes undefined\", \"Single lab per model\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided a structural/biochemical foothold by reconstituting the CRL3-LZTR1-MRAS complex and demonstrating CUL3-driven stabilization of LZTR1.\",\n      \"evidence\": \"BacMam expression, purification, and in vitro binding assays comparing MRAS, RIT1, and HRAS\",\n      \"pmids\": [\"40204202\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure reported in abstract\", \"Discrepancy with in vivo RIT1 preference unresolved\", \"Limited functional follow-up\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified small-molecule fragments that enhance the KRAS-LZTR1 interaction, establishing the complex as a druggable degradation-promoting target.\",\n      \"evidence\": \"Split-luciferase reporter, BioID, thermal shift, and NMR characterization of fragments C53/Z86\",\n      \"pmids\": [\"39194017\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vivo validation\", \"Effect on KRAS degradation not directly demonstrated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Uncovered a phosphorylation switch (PAK1/2-PP1C at RAS T148) and tissue context that set whether LZTR1 can degrade RAS, explaining differential RAS stability across cancers.\",\n      \"evidence\": \"Multi-omics in multiple myeloma cells, writer/eraser identification (PAK1/2, PP1C), T148 mutagenesis, LZTR1-dependent degradation and stability assays (preprint)\",\n      \"pmids\": [\"41542462\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not yet peer-reviewed\", \"Structural basis of how T148 phosphorylation blocks LZTR1 capture unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealed ubiquitination-independent functions—co-translational regulation of NF-kB1/MHC-I via ribosome/proteasome binding and disruption of LZTR1-NOC2L controlling p53 acetylation—broadening LZTR1 mechanism beyond RAS degradation.\",\n      \"evidence\": \"LZTR1 knockout epithelial organoids with NF-kB1 processing and ribosome/proteasome Co-IP and CD8+ TRM readouts; nanoluciferase PPI, phosphoproteomics, and p53-acetylation assays for NOC2L\",\n      \"pmids\": [\"41162356\", \"41175093\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of co-translational p50 regulation incompletely defined\", \"LZTR1-NOC2L interaction not independently replicated\", \"Connection to canonical CUL3 adaptor role unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Documented context-dependent pro-tumorigenic and cardiac roles—ERBB3/PYK2/SRC and actin-cytoskeleton effects in melanoma and RAP1/MAPK/AKT-driven cardiomyopathy—indicating LZTR1 output varies by tissue.\",\n      \"evidence\": \"BioID/Co-IP-MS with invasion and pathway assays in melanoma; cardiac-specific CASAAV Lztr1 knockdown mice with transcriptomics, Ca2+ handling, and apoptosis assays\",\n      \"pmids\": [\"40885854\", \"40967536\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct substrates underlying these phenotypes not defined\", \"Reconciliation of tumor-suppressive vs pro-invasive roles unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How LZTR1 integrates its many substrate axes—RAS/RIT1 degradation, RTK and CHMP1B turnover, KLHL12 repression, and ubiquitination-independent transcriptional/translational roles—into tissue-specific outputs, and how phosphorylation gating is structurally read out, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of substrate-bound CRL3-LZTR1\", \"Hierarchy and competition among substrates across cell types unmapped\", \"Mechanistic link between Golgi localization and ubiquitin ligase activity unestablished\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 3, 8, 12]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [1, 2, 4, 12]},\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [1, 3, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 3, 12]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 3, 12]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 12, 14, 15]}\n    ],\n    \"complexes\": [\"CRL3-LZTR1 (CUL3 RING E3 ligase)\"],\n    \"partners\": [\"CUL3\", \"KRAS\", \"HRAS\", \"MRAS\", \"RIT1\", \"CHMP1B\", \"EGFR\", \"AXL\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":6,"faith_total":6,"faith_pct":100.0}}